| 1000 | Humans |
| 996 | Coronavirus Infections |
| 995 | Pneumonia, Viral |
| 995 | Pandemics |
| 973 | Aged |
| 835 | Male |
| 821 | Betacoronavirus |
| 810 | Female |
| 774 | Middle Aged |
| 532 | Adult |
| 398 | Aged, 80 and over |
| 269 | Young Adult |
| 264 | Retrospective Studies |
| 210 | Adolescent |
| 151 | Risk Factors |
| 132 | Hospitalization |
| 122 | Severity of Illness Index |
| 105 | Child |
| 103 | Comorbidity |
| 97 | Treatment Outcome |
| 96 | China |
| 90 | Clinical Laboratory Techniques |
| 84 | Tomography, X-Ray Computed |
| 83 | Prognosis |
| 77 | Child, Preschool |
| 76 | Age Factors |
| 73 | Intensive Care Units |
| 72 | Cross-Sectional Studies |
| 70 | Italy |
| 67 | Risk Assessment |
| 67 | Lung |
| 63 | Infant |
| 63 | Hospital Mortality |
| 63 | Cohort Studies |
| 60 | Prospective Studies |
| 56 | Respiration, Artificial |
| 54 | Surveys and Questionnaires |
| 50 | United States |
| 48 | Time Factors |
| 47 | Incidence |
| 44 | Critical Illness |
| 43 | Disease Progression |
| 42 | C-Reactive Protein |
| 40 | Infant, Newborn |
| 39 | Quarantine |
| 39 | Biomarkers |
| 37 | Antibodies, Viral |
| 36 | Antiviral Agents |
| 35 | Respiratory Distress Syndrome, Adult |
| 34 | Follow-Up Studies |
| 33 | Sex Factors |
| 33 | Length of Stay |
| 30 | Prevalence |
| 30 | Nursing Homes |
| 30 | Anxiety |
| 29 | United Kingdom |
| 29 | Infection Control |
| 29 | Hydroxychloroquine |
| 28 | Health Personnel |
| 28 | Disease Outbreaks |
| 27 | Survival Analysis |
| 27 | Spain |
| 27 | RNA, Viral |
| 27 | Case-Control Studies |
| 26 | Social Isolation |
| 26 | Sensitivity and Specificity |
| 26 | Hypertension |
| 25 | Telemedicine |
| 25 | Neoplasms |
| 25 | Logistic Models |
| 25 | Fever |
| 24 | Stroke |
| 24 | Critical Care |
| 23 | Immunoglobulin G |
| 23 | Anti-Bacterial Agents |
| 23 | Age Distribution |
| 22 | France |
| 22 | Diabetes Mellitus |
| 21 | Survival Rate |
| 21 | Proportional Hazards Models |
| 20 | Respiratory Insufficiency |
| 20 | ROC Curve |
| 20 | Fibrin Fibrinogen Degradation Products |
| 20 | Emergency Service, Hospital |
| 19 | Symptom Assessment |
| 19 | Ritonavir |
| 19 | Real-Time Polymerase Chain Reaction |
| 19 | Predictive Value of Tests |
| 19 | Odds Ratio |
| 19 | Lopinavir |
| 19 | Germany |
| 19 | Dyspnea |
| 19 | Coronavirus |
| 18 | Severe Acute Respiratory Syndrome |
| 18 | Reverse Transcriptase Polymerase Chain Reaction |
| 18 | New York City |
| 18 | Mortality |
| 18 | Fatal Outcome |
| 18 | Depression |
| 18 | Contact Tracing |
| 18 | Brazil |
| 18 | Antibodies, Monoclonal, Humanized |
| 17 | Thrombosis |
| 17 | Tertiary Care Centers |
| 17 | Lymphocyte Count |
| 17 | Inflammation |
| 17 | Cytokines |
| 17 | Communicable Disease Control |
| 17 | Anticoagulants |
| 16 | Spike Glycoprotein, Coronavirus |
| 16 | Republic of Korea |
| 16 | Radiography, Thoracic |
| 16 | Mental Health |
| 16 | Interleukin-6 |
| 16 | Infectious Disease Transmission, Patient-to-Professional |
| 16 | Cough |
| 16 | Azithromycin |
| 16 | Aging |
| 15 | Time-to-Treatment |
| 15 | Registries |
| 15 | Neutrophils |
| 15 | Health Status Disparities |
| 15 | Exercise |
| 15 | Drug Combinations |
| 15 | Cardiovascular Diseases |
| 15 | Acute Kidney Injury |
| 14 | Reproducibility of Results |
| 14 | Leukocyte Count |
| 14 | Host-Pathogen Interactions |
| 14 | Hospitals, University |
| 14 | Homes for the Aged |
| 14 | Health Knowledge, Attitudes, Practice |
| 14 | Ethnic Groups |
| 14 | Delivery of Health Care |
| 14 | Cause of Death |
| 13 | Viral Load |
| 13 | Socioeconomic Factors |
| 13 | Public Health |
| 13 | Patient Discharge |
| 13 | Mass Screening |
| 13 | Diagnosis, Differential |
| 12 | Serologic Tests |
| 12 | Seroepidemiologic Studies |
| 12 | Renal Dialysis |
| 12 | Pulmonary Disease, Chronic Obstructive |
| 12 | Population Surveillance |
| 12 | Patient Admission |
| 12 | Palliative Care |
| 12 | Oxygen Inhalation Therapy |
| 12 | Nasopharynx |
| 12 | Lymphopenia |
| 11 | Stress, Psychological |
| 11 | Sex Distribution |
| 11 | Risk |
| 11 | Pulmonary Embolism |
| 11 | Personal Protective Equipment |
| 11 | Models, Statistical |
| 11 | Loneliness |
| 11 | Japan |
| 11 | Internet |
| 11 | Inpatients |
| 11 | Hypoxia |
| 11 | Disease Transmission, Infectious |
| 11 | Diabetes Mellitus, Type 2 |
| 11 | Body Mass Index |
| 11 | Australia |
| 11 | Animals |
| 11 | African Americans |
| 10 | Social Media |
| 10 | Polymerase Chain Reaction |
| 10 | Peptidyl-Dipeptidase A |
| 10 | Multivariate Analysis |
| 10 | Longitudinal Studies |
| 10 | Liver Diseases |
| 10 | Hospitals |
| 10 | Heart Diseases |
| 10 | Health Services Accessibility |
| 10 | Glucocorticoids |
| 10 | Geriatric Assessment |
| 10 | Ferritins |
| 10 | Family |
| 10 | Cytokine Release Syndrome |
| 10 | Cross Infection |
| 10 | Coinfection |
| 10 | Cluster Analysis |
| 10 | Chronic Disease |
| 10 | Area Under Curve |
| 9 | Ultrasonography |
| 9 | Triage |
| 9 | Thrombolytic Therapy |
| 9 | Quality of Life |
| 9 | Obesity |
| 9 | Noninvasive Ventilation |
| 9 | Kidney Failure, Chronic |
| 9 | Intubation, Intratracheal |
| 9 | Immunoglobulin M |
| 9 | Heart Failure |
| 9 | Health Behavior |
| 9 | European Continental Ancestry Group |
| 9 | Drug Therapy, Combination |
| 9 | Combined Modality Therapy |
| 9 | Asymptomatic Infections |
| 9 | Asymptomatic Diseases |
| 9 | Acute Disease |
| 8 | Referral and Consultation |
| 8 | Randomized Controlled Trials as Topic |
| 8 | Practice Guidelines as Topic |
| 8 | Patient Safety |
| 8 | Patient Isolation |
| 8 | Oxygen |
| 8 | Outcome Assessment, Health Care |
| 8 | Lymphocytes |
| 8 | Israel |
| 8 | Immunization, Passive |
| 8 | Host Microbial Interactions |
| 8 | Global Health |
| 8 | Fear |
| 8 | Fatigue |
| 8 | England |
| 8 | Databases, Factual |
| 7 | Vulnerable Populations |
| 7 | Vitamin D |
| 7 | Travel |
| 7 | Terminal Care |
| 7 | Social Distance |
| 7 | Renal Insufficiency, Chronic |
| 7 | Prone Position |
| 7 | Procalcitonin |
| 7 | Pregnancy |
| 7 | Practice Patterns, Physicians' |
| 7 | Postoperative Complications |
| 7 | Pneumonia |
| 7 | Platelet Count |
| 7 | Patient Selection |
| 7 | Patient Acceptance of Health Care |
| 7 | Occupational Diseases |
| 7 | Masks |
| 7 | Long-Term Care |
| 7 | L-Lactate Dehydrogenase |
| 7 | Kaplan-Meier Estimate |
| 7 | Iran |
| 7 | India |
| 7 | Health Status |
| 7 | Health Policy |
| 7 | Hand Disinfection |
| 7 | Genome, Viral |
| 7 | Frail Elderly |
| 7 | Forecasting |
| 7 | Emergencies |
| 7 | Elective Surgical Procedures |
| 7 | Early Diagnosis |
| 7 | Drug Administration Schedule |
| 7 | Clinical Decision-Making |
| 7 | CD4-Positive T-Lymphocytes |
| 7 | Antimalarials |
| 7 | Algorithms |
| 7 | Adrenal Cortex Hormones |
| 7 | Adaptation, Psychological |
| 6 | Virus Shedding |
| 6 | Telephone |
| 6 | Sweden |
| 6 | Social Support |
| 6 | Smoking |
| 6 | Seroconversion |
| 6 | Sepsis |
| 6 | Self Report |
| 6 | Sampling Studies |
| 6 | ST Elevation Myocardial Infarction |
| 6 | Respiratory Therapy |
| 6 | Respiratory Function Tests |
| 6 | Research Design |
| 6 | Propensity Score |
| 6 | Occupational Exposure |
| 6 | Nucleocapsid Proteins |
| 6 | New York |
| 6 | Nervous System Diseases |
| 6 | Models, Theoretical |
| 6 | Minority Groups |
| 6 | Magnetic Resonance Imaging |
| 6 | Machine Learning |
| 6 | Long QT Syndrome |
| 6 | Immunoassay |
| 6 | Hispanic Americans |
| 6 | Healthcare Disparities |
| 6 | Health Surveys |
| 6 | Health Services Needs and Demand |
| 6 | HIV Infections |
| 6 | Feasibility Studies |
| 6 | Employment |
| 6 | Electronic Health Records |
| 6 | Diabetes Complications |
| 6 | Computer Simulation |
| 6 | Communication |
| 6 | CD8-Positive T-Lymphocytes |
| 6 | Attitude to Health |
| 6 | Anti-Inflammatory Agents |
| 6 | Angiotensin-Converting Enzyme Inhibitors |
| 5 | Venous Thromboembolism |
| 5 | Tracheostomy |
| 5 | T-Lymphocytes |
| 5 | Surgical Procedures, Operative |
| 5 | Stroke Volume |
| 5 | Singapore |
| 5 | Self Care |
| 5 | Saudi Arabia |
| 5 | Protective Factors |
| 5 | Pilot Projects |
| 5 | Percutaneous Coronary Intervention |
| 5 | Patient Care Team |
| 5 | Oceanic Ancestry Group |
| 5 | Observational Studies as Topic |
| 5 | Netherlands |
| 5 | Needs Assessment |
| 5 | Myocardial Infarction |
| 5 | Multiple Organ Failure |
| 5 | Morbidity |
| 5 | Monitoring, Physiologic |
| 5 | Methylprednisolone |
| 5 | Mental Disorders |
| 5 | Lung Neoplasms |
| 5 | Kidney |
| 5 | Interpersonal Relations |
| 5 | Influenza, Human |
| 5 | Immunotherapy |
| 5 | Immunosuppressive Agents |
| 5 | Health Care Rationing |
| 5 | Geriatrics |
| 5 | Gastrointestinal Hemorrhage |
| 5 | Gastrointestinal Diseases |
| 5 | Frailty |
| 5 | Feeding Behavior |
| 5 | Family Characteristics |
| 5 | Europe |
| 5 | Enzyme Inhibitors |
| 5 | Diarrhea |
| 5 | Denmark |
| 5 | Demography |
| 5 | Continuous Positive Airway Pressure |
| 5 | Continental Population Groups |
| 5 | Computed Tomography Angiography |
| 5 | Cerebrovascular Disorders |
| 5 | Cerebral Hemorrhage |
| 5 | Brain Ischemia |
| 5 | Bacterial Infections |
| 5 | Autopsy |
| 5 | Aspartate Aminotransferases |
| 5 | Antineoplastic Agents, Immunological |
| 5 | APACHE |
| 4 | Wounds and Injuries |
| 4 | World Health Organization |
| 4 | Whole Genome Sequencing |
| 4 | Venous Thrombosis |
| 4 | Utah |
| 4 | Urban Population |
| 4 | Uncertainty |
| 4 | Turkey |
| 4 | Troponin I |
| 4 | Thrombocytopenia |
| 4 | Thrombectomy |
| 4 | Taiwan |
| 4 | Survivors |
| 4 | Standard of Care |
| 4 | Specimen Handling |
| 4 | Skilled Nursing Facilities |
| 4 | Signal Transduction |
| 4 | Shock |
| 4 | Scotland |
| 4 | Respiratory Tract Infections |
| 4 | Resource Allocation |
| 4 | Regression Analysis |
| 4 | Recurrence |
| 4 | Quality of Health Care |
| 4 | Public Opinion |
| 4 | Population Density |
| 4 | Poland |
| 4 | Pneumothorax |
| 4 | Pneumonia, Bacterial |
| 4 | Physicians |
| 4 | Patient Positioning |
| 4 | Overweight |
| 4 | Outcome and Process Assessment, Health Care |
| 4 | Olfaction Disorders |
| 4 | Nutritional Status |
| 4 | Nomograms |
| 4 | Mutation |
| 4 | Multimorbidity |
| 4 | Molecular Diagnostic Techniques |
| 4 | Mass Media |
| 4 | Lung Diseases |
| 4 | Lung Diseases, Interstitial |
| 4 | Liver Function Tests |
| 4 | Kidney Diseases |
| 4 | Intracranial Hemorrhages |
| 4 | Information Dissemination |
| 4 | Infectious Disease Transmission, Professional-to-Patient |
| 4 | Income |
| 4 | Immunocompromised Host |
| 4 | Hospitals, Community |
| 4 | Heparin, Low-Molecular-Weight |
| 4 | Hemoglobins |
| 4 | Heart Arrest |
| 4 | Health Services for the Aged |
| 4 | Health Resources |
| 4 | General Practice |
| 4 | Enzyme-Linked Immunosorbent Assay |
| 4 | Emigrants and Immigrants |
| 4 | Emergency Medical Services |
| 4 | Electrocardiography |
| 4 | Dietary Supplements |
| 4 | Delivery of Health Care, Integrated |
| 4 | Delirium |
| 4 | Critical Pathways |
| 4 | Cost of Illness |
| 4 | Coronary Angiography |
| 4 | Continuity of Patient Care |
| 4 | Communicable Diseases, Emerging |
| 4 | Cognitive Dysfunction |
| 4 | Cities |
| 4 | Caregivers |
| 4 | CD4 Lymphocyte Count |
| 4 | Breast Neoplasms |
| 4 | Blood Glucose |
| 4 | Blood Gas Analysis |
| 4 | Blood Coagulation |
| 4 | Blood Coagulation Disorders |
| 4 | Artificial Intelligence |
| 4 | Antirheumatic Agents |
| 4 | Antigens, CD |
| 4 | Anti-Infective Agents |
| 4 | Ambulatory Care Facilities |
| 4 | Alzheimer Disease |
| 4 | Alanine Transaminase |
| 4 | Aerosols |
| 4 | Activities of Daily Living |
| 3 | Vitamins |
| 3 | Vitamin D Deficiency |
| 3 | Virus Replication |
| 3 | Virulence |
| 3 | Viremia |
| 3 | Victoria |
| 3 | Veterans |
| 3 | Vero Cells |
| 3 | Vaccination |
| 3 | Up-Regulation |
| 3 | Trust |
| 3 | Transcatheter Aortic Valve Replacement |
| 3 | Thromboembolism |
| 3 | Thorax |
| 3 | Texas |
| 3 | Surgeons |
| 3 | Stomach Neoplasms |
| 3 | Spatial Analysis |
| 3 | Social Class |
| 3 | Social Behavior |
| 3 | Smartphone |
| 3 | Sleep Initiation and Maintenance Disorders |
| 3 | Single-Cell Analysis |
| 3 | Seasons |
| 3 | Safety |
| 3 | Rural Population |
| 3 | Rheumatic Diseases |
| 3 | Residence Characteristics |
| 3 | Remote Consultation |
| 3 | Recovery of Function |
| 3 | Receptors, Interleukin-6 |
| 3 | Radiography |
| 3 | Pulmonary Artery |
| 3 | Proof of Concept Study |
| 3 | Prealbumin |
| 3 | Postoperative Period |
| 3 | Positive-Pressure Respiration |
| 3 | Polymorphism, Single Nucleotide |
| 3 | Politics |
| 3 | Point-of-Care Systems |
| 3 | Pneumonia, Ventilator-Associated |
| 3 | Pleural Effusion |
| 3 | Phylogeny |
| 3 | Phenotype |
| 3 | Pharynx |
| 3 | Peritoneal Dialysis |
| 3 | Peptide Fragments |
| 3 | Patient Satisfaction |
| 3 | Patient Acuity |
| 3 | Occupational Health |
| 3 | Norway |
| 3 | New Zealand |
| 3 | New South Wales |
| 3 | Neutralization Tests |
| 3 | Neural Networks, Computer |
| 3 | Neoplasm Staging |
| 3 | Natriuretic Peptide, Brain |
| 3 | Monocytes |
| 3 | Mobile Applications |
| 3 | Middle East Respiratory Syndrome Coronavirus |
| 3 | Mice |
| 3 | Mexico |
| 3 | Medical Staff, Hospital |
| 3 | Medical Oncology |
| 3 | Mediastinal Emphysema |
| 3 | Luminescent Measurements |
